Sun Pharma Advanced Research Company Ltd

SPARC Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sun Pharma Advanced Research Company Ltd

₹ 159 2.13%
11 Jul - close price
sparc.life BSE: 532872 NSE: SPARC
About

Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.[1]

Key Points

Leadership[1]
First listed pharma R&D company out of India where founders still own 70% and continue to invest.

Website BSE NSE
  • Market Cap ₹ 5,171 Cr.
  • Current Price ₹ 159
  • High / Low ₹ 241 / 109
  • Stock P/E
  • Book Value ₹ -6.80
  • Dividend Yield 0.00 %
  • ROCE -298 %
  • ROE %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -1.35% over past five years.
  • Company might be capitalizing the interest cost
  • Promoter holding has decreased over last 3 years: -3.42%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap Nifty Microcap 250 Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
25 28 32 131 48 24 21 14 17 17 13 15 27
92 107 94 115 137 126 113 116 124 112 117 89 81
Operating Profit -67 -78 -63 16 -90 -102 -91 -103 -108 -95 -104 -74 -54
OPM % -264% -275% -198% 12% -188% -427% -432% -740% -649% -566% -808% -499% -198%
0 0 0 0 11 10 8 6 4 2 0 0 0
Interest 2 2 3 3 0 0 0 0 1 1 1 3 5
Depreciation 3 3 3 3 3 3 3 3 3 3 3 3 3
Profit before tax -71 -82 -68 10 -82 -95 -86 -100 -107 -97 -108 -80 -61
Tax % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
-71 -82 -68 10 -82 -95 -86 -100 -107 -97 -108 -80 -61
EPS in Rs -2.61 -3.03 -2.52 0.37 -2.53 -2.94 -2.66 -3.07 -3.29 -2.98 -3.32 -2.46 -1.88
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
167 156 161 181 78 183 77 253 137 239 76 72
134 191 224 304 321 334 387 388 324 453 479 399
Operating Profit 34 -35 -63 -123 -243 -151 -310 -135 -187 -214 -404 -327
OPM % 20% -23% -39% -68% -310% -83% -404% -53% -136% -90% -534% -456%
10 3 3 14 54 14 10 5 7 11 29 2
Interest 6 0 2 2 0 0 3 11 13 8 2 9
Depreciation 4 7 8 8 8 8 9 11 10 12 12 11
Profit before tax 34 -40 -70 -119 -197 -145 -312 -151 -203 -223 -388 -345
Tax % 12% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
30 -40 -70 -119 -197 -145 -312 -151 -203 -223 -388 -345
EPS in Rs 1.23 -1.60 -2.83 -4.82 -7.85 -5.55 -11.92 -5.77 -7.48 -6.86 -11.96 -10.64
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -7%
5 Years: -1%
3 Years: -19%
TTM: -5%
Compounded Profit Growth
10 Years: %
5 Years: -2%
3 Years: -30%
TTM: 11%
Stock Price CAGR
10 Years: -9%
5 Years: -1%
3 Years: -9%
1 Year: -32%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 24 24 24 25 25 26 26 26 27 32 32 32
Reserves 116 76 8 133 160 270 -45 -194 4 480 92 -253
5 4 56 3 2 2 67 236 79 16 56 265
39 39 75 111 122 101 224 162 170 302 305 284
Total Liabilities 184 143 163 273 309 398 273 230 280 830 486 329
64 67 70 69 52 58 104 91 92 106 103 149
CWIP 1 0 1 1 3 24 32 5 26 27 44 1
Investments 6 0 0 10 108 211 8 6 12 291 2 0
112 76 92 192 146 106 128 127 150 406 338 179
Total Assets 184 143 163 273 309 398 273 230 280 830 486 329

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
37 -41 -44 -128 -183 -172 -211 -152 -208 -69 -429 -362
44 53 -13 -7 -105 -102 155 2 -29 -548 391 158
-81 -1 51 194 224 274 55 159 229 617 43 201
Net Cash Flow -0 11 -7 60 -63 0 0 9 -8 -1 4 -4

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 61 47 21 78 82 20 76 25 74 50 75 82
Inventory Days 0 0 0 0 0 0 0 0 0
Days Payable
Cash Conversion Cycle 61 47 21 78 82 20 76 25 74 50 75 82
Working Capital Days 129 21 -42 -59 -232 -98 -557 -96 -97 -189 -509 -962
ROCE % 21% -32% -71% -94% -143% -62% -183% -242% -218% -67% -109% -298%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
69.09% 69.09% 68.23% 65.68% 65.68% 65.68% 65.68% 65.68% 65.68% 65.68% 65.68% 65.68%
2.40% 2.38% 3.48% 3.64% 3.64% 3.67% 3.30% 3.24% 2.64% 2.15% 2.23% 1.45%
0.76% 0.76% 0.76% 0.63% 0.63% 0.65% 0.67% 0.67% 0.17% 0.21% 0.64% 1.13%
27.75% 27.77% 27.53% 30.04% 30.06% 29.99% 30.36% 30.41% 31.51% 31.96% 31.47% 31.76%
No. of Shareholders 94,49493,71896,33798,7771,00,8071,01,4331,03,9901,02,7431,25,1841,28,2051,31,0341,42,864

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls